Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation (EFA-1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of the study was to determine the influence of fluvastatin and atorvastatin on platelet aggregation in patients treated with aspirin and plavix after coronary stenting. We hypothezied a positive effect of fluvastatin on platelet aggregation levels.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 95 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
all patients with stent implantation followed by treatment with aspirin and clopidogrel
routinely treated with acetylsalicylic 100 mg/day
acute coronary syndrome
use of a GPIIb/IIIa inhibitor
allergy to acetylsalicylic acid, clopidogrel, statins
elevated liver enzymes (> 3 x norm value)
active liver disease
recent gastrointestinal bleeding (< 3 months)
known platelet dysfunction or abnormal platelet count
indication for treatment with non-steroidal drugs
indication for long-term treatment with a drug metabolized by cytochrome p450 3A4 or 2C9